Should You Worry About Novavax's Latest Delay?
Novavax (NASDAQ: NVAX) investors were just about to breathe a sigh of relief. A U.S. Food and Drug Administration (FDA) advisory committee earlier this week recommended that the agency authorize Novavax's coronavirus vaccine.
This comes after other delays. Novavax initially planned on requesting authorization in the first half of last year -- but challenges in a manufacturing ramp-up slowed things down. Then, after Novavax requested authorization in January, the FDA didn't make an immediate decision. Instead, it scheduled its advisory committee meeting for June.
After this week's panel vote, investors expected the FDA to quickly follow the recommendation and authorize the vaccine. But the agency said it needs more time. That's because Novavax submitted new manufacturing data earlier in the month, and the FDA wants to study that data. If you hold Novavax shares or are considering buying shares, should you be worried about this latest delay?
Source Fool.com
